Alzheimer's: "We Now Have Clear Targets"
In late October, Amgen Inc. announced the breakthrough discovery of one of the key triggers of Alzheimer's disease: an enzyme that sparks formation of the plaque deposits that clog the brains of its victims. The finding was reported one day before the annual meeting of the Society for Neuroscience, where, in three days, attendees heard about more advances in Alzheimer's than they had seen in decades. Elan Pharmaceuticals and SmithKline Beecham announced results of their work on a plaque-forming enzyme. Other scientists elaborated on the discovery only a few months ago of a different potential plaque trigger. And dozens of research teams reported findings on new drugs, diagnostic markers, and disease mechanisms. "This is a very, very exciting time in Alzheimer's research," says Dr. Dennis J. Selkoe, director of the Center for Neurologic Diseases at Brigham & Women's Hospital in Boston. "We now have clear targets" for drugs that inhibit the disease.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- One of the World’s Hottest Stocks Is Now Tumbling
- This Rare Bear Who Called the Crash Warns Housing Is Too Hot Again
- Recent ‘Odd’ Market Moves May Be a Warning Sign for Stocks
- The Global Economy Is Doing Just Fine, But the Davos Elite Is Worried
- U.S. Stocks Gain as Senate Votes to End Shutdown: Markets Wrap